DEREK GRIFFITH: Open Payments
NPI 1841999505 · PAHRUMP, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,747 in 63 payments from 7 companies in 2025. Trend: 2023 $153 · 2024 $253 · 2025 $1,747
Food & beverage: $1,747
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $633 |
| Otsuka America Pharmaceutical, Inc. | 17 | $477 |
| Alkermes, Inc. | 9 | $252 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $220 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: VRAYLAR, REXULTI, ARISTADA, CAPLYTA, Auvelity, INGREZZA, NUEDEXTA, Qelbree.
Industry payments across NV — which companies pay providers there.
